Page last updated: 2024-08-21

quinazolines and Angiogenesis, Pathologic

quinazolines has been researched along with Angiogenesis, Pathologic in 220 studies

Research

Studies (220)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (0.91)	18.2507
2000's	109 (49.55)	29.6817
2010's	105 (47.73)	24.3611
2020's	4 (1.82)	2.80

Authors

Authors	Studies
Deng, Y; Li, X	1
Baietti, MF; Criem, N; Impens, F; Lechat, B; Pandolfi, S; Quarck, R; Sablina, AA; Sewduth, RN; Sheryazdanova, A; Steklov, M; Zhao, P	1
Chen, DL; Hu, L; Huang, SY; Jiang, R; Li, DY; Li, GL; Li, J; Li, LS; Li, XP; Ran, JH; Wang, YP; Zeng, D; Zhao, S; Zhou, P	1
Borghi, MO; Cantone, MC; Carra, S; Dicitore, A; Gaudenzi, G; Ghilardi, A; Hofland, LJ; Persani, L; Plebani, A; Saronni, D; Vitale, G	1
Carter, R; Hagan, AE; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, GJ; Sharma, RA; Westhorpe, A; Znati, SA	1
Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C	1
Chen, H; Deng, Y; Ding, L; Guo, J; Huang, X; Li, H; Tan, F; Wang, Y; Yang, G; Yu, B; Yu, P	1
Hao, L; Hu, H; Jiang, Q; Li, X; Wang, G; Yan, B; Yao, J; Zhu, Y	1
Guo, J; Guo, T; Liu, D; Sun, Y; Wang, N; Zhu, X	1
Borchmann, S; Büttner, R; Dietlein, F; Florin, A; Golfmann, K; Hallek, M; Koker, M; Malchers, F; Meder, L; Rodrik-Outmezguine, V; Rosen, N; Tharun, L; Ullrich, RT; Volz, C	1
Chen, H; Ju, X; Song, Z; Wang, Y; Wu, W; Yan, T; Yang, X; Zhang, Z	1
Heymach, J; Nakano, T; Nowak, AK; Popat, S; Scagliotti, GV; Tsao, A	1
Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW	1
Ponnurangam, S; Rangarajan, P; Standing, D; Subramaniam, D	1
Brekken, RA; Buettner, R; Chatterjee, S; Christofori, G; Frasca, D; Heukamp, LC; Koker, M; König, K; Meder, L; Neumaier, B; Peifer, M; Rauh, D; Schöttle, J; Siobal, M; Thomas, RK; Ullrich, RT; Wieczorek, C; Wolf, J	1
Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC	1
Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P	1
Batchelor, TT; de Groot, J; Reardon, DA	1
Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A	1
Fu, LX; Tang, DM; Wang, Y; Yan, HX; Yang, XN	1
Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A	1
Brun, P; Castagliuolo, I; Chilin, A; Conconi, MT; Di Liddo, R; Ferrarese, A; Guiotto, A; Marzaro, G; Tonus, F; Urbani, L; Zanusso, I	1
Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS	1
Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB	1
Klempner, SJ; Mills, GB; Myers, AP; Westin, SN	1
Agar, JN; Agar, NY; Alberta, J; Davis, E; Easterling, ML; Ebling, MC; Ide, JL; Kellersberger, KA; Kesari, S; Liu, X; Marchionni, MA; Norton, I; Santagata, S; Sauvageot, CM; Stiles, CD; Stuart, DD; Wang, LY	1
Gillespie, GY; Green, SC; Lobo, MR; Pike, MM; Schabel, MC; Woltjer, RL	1
Amantini, C; Berardi, R; Burattini, L; Cascinu, S; Conti, A; Muzzonigro, G; Santoni, G; Santoni, M	1
Fujii, T; Fujiwara, M; Fukuda, S; Hotta, Y; Kanda, M; Kasuya, H; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Nomoto, S; Sahin, TT; Sugimoto, H; Tan, G; Tanaka, C; Tanaka, M; Tsurumaru, N; Yamada, S; Yamamura, K	1
Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F	1
Becker, J; Bicknell, R; Bikfalvi, A; Exertier, P; Franco, M; Godard, V; Hagedorn, M; Herbert, J; Javerzat, S; Nivelles, O; Ormenese, S; Pineau, R; Platonova, N; Pujol, N; Wang, B; Wilting, J; Winandy, M	1
Dinya, E; Fazekas, A; Gyorfi, A; Gyurkovics, M; Lohinai, Z; Rosivall, L; Székely, DA	1
Leung, KN; Liao, X; Mak, NK; Zhou, X	1
Biersack, B; Ficner, R; Mahal, K; Mueller, T; Resch, M; Schobert, R	1
Barczyk, A; Cagnon, A; Depreux, P; Garofalo, A; Goossens, L; Ravez, S; Six, P	1
Harada, D; Honda, Y; Ichihara, E; Kiura, K; Murakami, T; Ninomiya, T; Ochi, N; Ohashi, K; Takigawa, N; Tanimoto, M; Yasugi, M	1
Chen, L; Li, Q; Liu, XD; Wu, B; Xu, HF; Zhan, YH; Zhang, HH	1
Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L	1
Ito, K; Sugino, K; Takami, H	1
Chen, M; Gao, B; Qin, X; Wang, J; Wang, Y; Zhang, Z	1
Coussy, F; Cuvier, C; Espié, M; Giacchetti, S; Hocini, H; Teixeira, L	1
Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J; Zuo, Y	1
Ghosh, G; Guo, B; Wu, Y	1
Lee, JG; Wu, R	1
Jin, ZX; Liu, F; Liu, YX; Min, SY; Wang, L; Zhang, XX; Zhu, ZL; Zuo, Z	1
Bae, JS; Choi, YS; Lee, SH; Lee, YM; Oh, SY; Seok, JY	1
Anto, RJ; Antony, J; Chandran, H; Joseph, SM; Katiki, MR; Murty, MS; Nath, LR; Nishanth, KS; Panakkal, EJ; Paul, A; Rajan, E; Ran, S; Saikia, M; Sankar, S; Shabna, A; Sridivya, I; Sriramya, I; Vinod, V	1
Cascone, T; Heymach, JV	1
Allen, D; Bokobza, SM; Devery, AM; Jiang, Y; Kersemans, V; Ryan, AJ; Smart, S	1
Basha, SA; Bhadra, MP; Bhadra, U; Kamal, A; Kavi Kishor, PB; Lavanya, A; Ramaiah, MJ; Srinivas, C; Yerramsetty, S	1
Bièche, I; Bonin, F; Château-Joubert, S; de Plater, L; Dieras, V; El Botty, R; Hatem, R; Labiod, D; Marangoni, E; Servely, JL; Vacher, S	1
Bracchi, C; De Medici, C; Gasparri, ML; Imboden, S; Marchetti, C; Mueller, MD; Muzii, L; Palaia, I; Panici, PB; Papadia, A; Ruscito, I	1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C	1
Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R	1
Choe, J; Han, M; Jeoung, D; Kim, H; Kim, Y; Kim, YM; Lee, H; Lee, YS; Park, D	1
Amoozgar, Z; Batchelor, TT; Batista, A; Chatterjee, S; Datta, M; Duda, DG; Farrar, CT; Fukumura, D; Goveia, J; Huang, Y; Jain, RK; Jung, K; Kamoun, WS; Kirkpatrick, ND; Kloepper, J; Leow, CC; Marijt, KA; Muzikansky, A; Peterson, TE; Seano, G; Snuderl, M; Vardam, T; Xu, L	1
Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M	1
Liu, Q; Liu, Y; Luo, F; Shi, L; Yang, F; Zhang, F; Zou, M	1
Chen, Y; Dong, Y; Jiang, Z; Li, Y; Pei, H; Peng, Y; Shao, T; Sun, Z; Tang, W; Wang, J; Yi, Z; Zhou, W	1
Fang, S; Han, X; Tang, N; Wang, Z; Zhang, Q	1
Chen, Y; Chen, ZS; Huang, JR; Jiang, QW; Li, Y; Qin, WM; Qiu, JG; Shi, Z; Wang, K; Wang, YJ; Wei, MN; Yang, DH; Yang, Y; Zhang, WJ; Zheng, DW	1
Ahmadinia, L; Alimoghaddam, K; Amanpour, S; Barghi, F; Dardaei, L; Dehpour, AR; Emami, AH; Eyvani, H; Ghaffari, SH; Ghavamzadeh, A; Ghazi-Khansari, M; Gortany, NK; Mirshahvaladi, S; Moghaddaskho, F; Momeny, M; Sabourinejad, Z; Tavangar, SM; Yousefi, H; Zarrinrad, G	1
Boyun, S; Hongyi, H; Jiang, L; Jianye, Y; Ping, T; Shiying, W; Wanjun, Z	1
Natale, RB	2
Alitalo, K; Heckman, CA; Holopainen, T; Jeltsch, M; Jürgensmeier, JM; Keskitalo, S; Wedge, SR; Wirzenius, M; Ylä-Herttuala, S	1
Herder, GJ; Lind, JS; Smit, EF	1
Adam, L; Bar-Eli, M; Black, PC; Brown, GA; Dinney, CP; Fisher, MB; Gallagher, D; Inamoto, T; Kassouf, W; Luongo, T; McConkey, DJ	1
Bozec, A; Cayre, A; Dental, C; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Gros, FX; Milano, G; Penault-Llorca, F	1
Kawabe, J; Ohsaki, Y; Osanai, S; Sasaki, T; Shibukawa, K; Tanno, S	1
Jing, DD; Lu, YY; Wang, XP; Wu, K; Xu, M	1
Angagaw, MH; Bettano, KA; Chenard, M; Haines, BB; Reilly, JF; Sevilla, RS; Sur, C; Tong, C; Ware, C; Winkelmann, CT; Zhang, W	1
Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL	1
Batchelor, TT; di Tomaso, E; Duda, DG; Gerstner, ER; Ivy, P; Jain, RK; Loeffler, JS; Ryg, PA; Sorensen, AG	1
Finn, RS; Zhu, AX	1
de Boüard, S; Guillamo, JS; Leuraud, P; Marie, Y; Marteau, L; Parienti, JJ; Peschanski, M; Poupon, MF; Raymond, E; Valable, S	1
Cassidy, J; Lindsay, CR; MacPherson, IR	1
Hu, C; Jiang, J	1
Norris, CM; Ryan, A; Shi, W; Siemann, DW	1
Elenius, K; Grenman, R; Iivanainen, E; Kulmala, J; Lauttia, S; Salven, P; Tvorogov, D; Zhang, N	1
Hsu, JY; Wakelee, HA	1
Berndt, A; Cesca, M; D'Incalci, M; Frapolli, R; Giavazzi, R; Kosmehl, H; Richter, P; Ryan, AJ; Scarlato, V	1
Kanda, S; Miyata, Y; Naba, A	1
Wachsberger, P; Yan, K; Yu, Y	1
Drevs, J; Esser, N; Jürgensmeier, JM; Medinger, M; Ryan, A; Zirrgiebel, U	1
Fang, W; Heymach, JV; Nilsson, MB; Palla, S; Zage, PE; Zeng, L; Zweidler-McKay, PA	1
Cheng, SY; Chiou, SH; Feng, H; Hu, B; Lieberman, FS; Liu, KW; Ma, HI; Sarkaria, JN; Schornack, PA; Sengar, RS; Wiener, EC; Yiin, JJ	1
Biasco, G; Boschi, S; Dissoki, S; Fanti, S; Landuzzi, L; Lodi, F; Lollini, PL; Mishani, E; Nanni, C; Nicoletti, G; Pantaleo, MA; Paterini, P; Piccaluga, PP	1
Brekken, RA; Carney, DN; Korpanty, G; Smyth, E; Sullivan, LA	1
Chan, AW; di Tomaso, E; Jain, RK; Kamoun, WS; Lahdenranta, J; McClatchey, AI; Plotkin, SR; Wong, HK	1
Calvo, A; Catena, R; Collantes, M; Diaz, R; Díaz-González, JA; Manrique, I; Nguewa, PA; Parrondo, R; Peñuelas, I; Perez-Stable, C; Redrado, M	1
Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM	1
Dempsey, EC; Karoor, V; Le, M; Merrick, D; Miller, YE	1
Lam, KC; Mok, TS	1
Moulder, SL	1
Chen, X; Hoffman, L; Lee, TY; Ryan, AJ; Tai, JH; Tessier, J	1
Kelly, K; Linnoila, RI; Munasinghe, J; Yin, JJ; Zhang, L	1
Doçi, CL; Hasina, R; Lingen, MW; Mankame, TP; Wroblewski, K; Zhou, G	1
Goto, H; Li, Q; Nakataki, E; Nishioka, Y; Ogino, H; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yano, S	1
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R	1
Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N	1
Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V	1
Bankson, JA; Chen, Y; Frederick, MJ; Galer, CE; Gule, MK; Henderson, YC; Jasser, SA; Lai, SY; Milas, ZL; Myers, JN; Sano, D; Schwartz, DL; Zhao, M; Zhou, G	1
Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P	1
Hanna, EY; Heymach, J; Matsumoto, F; Milas, L; Molkentine, DP; Myers, JN; Papadimitrakopoulou, V; Sano, D; Takahashi, Y; Valdecanas, DR; Zhao, M	1
Beckman, JA; Burstein, HJ; Dallabrida, SM; Hannagan, K; Ismail, NS; Mayer, EL; Redline, WM; Rupnick, MA	1
Cao, Z; Cheng, L; Dai, L; Deng, H; Deng, S; Feng, S; Li, W; Liu, S; Liu, Y; Ma, Y; Pan, Y; Shen, G; Shi, S; Tian, H; Wang, W; Wei, Y; Xie, H; Yang, S; Yang, Y; Zhang, N; Zhang, S; Zhao, C; Zhao, X; Zheng, R	1
Berglund, C; Chernoguz, A; Crawford, K; Cripe, TP; Donovan, E; Frischer, JS; Vandersall, A	1
Lenihan, DJ; Subbiah, IM; Tsimberidou, AM	1
Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA	1
Fiedler, W; Wellbrock, J	1
Langenkamp, E; Leenders, WP; Molema, G; Moorlag, HE; St Croix, B; Zwiers, PJ	1
Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT	1
Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II	1
Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H	1
Akama-Garren, EH; Edalati, A; Lindstrom, TM; Petralia, JD; Robinson, WH; Ruiz, PJ; Stein, EA; Swanson, CD	1
Döme, B; Török, S	1
Aglietta, M; Cavalloni, G; Gammaitoni, L; Leone, F; Marchiò, S; Migliardi, G; Peraldo-Neia, C; Sarotto, I; Soster, M	1
Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W	1
Dempsey, EC; Fagan, KA; Karoor, V; Le, M; Merrick, D; Miller, YE	1
Donev, IS; Kita, K; Li, Q; Matsumoto, K; Nakagawa, T; Nakamura, T; Nishioka, Y; Shimizu, E; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S	1
Rudà, R; Soffietti, R; Trevisan, E	1
Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S	1
Ang, JE; Brunetto, A; Castellano, I; Collins, DJ; deBono, JS; deSouza, NM; Ghiorghiu, D; Kaye, SB; Leach, MO; Mann, H; Marley, S; Mears, D; Messiou, C; Morgan, VA; Orton, M; Papadatos-Pastos, D; Tessier, J; Tunariu, N; Young, H	1
Abou-Alfa, GK; Ang, C; O'Reilly, EM	1
Bodor, C; Dinya, E; Győrfi, A; Gyurkovics, M; Lohinai, Z; Rosivall, L; Székely, AD	1
Burstein, HJ; Chen, WY; Downing, SR; Gelman, R; Hannagan, K; Isakoff, SJ; Klement, G; Mayer, EL; Winer, EP	1
Pfister, C; Pfrommer, H; Roser, F; Tatagiba, MS	1
Ager, E; Chung, E; Duyverman, AM; Eichler, AF; Engelman, JA; Farrar, CT; Fukumura, D; Goel, S; Hiddingh, L; Huang, Y; Incio, J; Jain, RK; Kamoun, W; Kodack, DP; Lussiez, A; Mahmood, S; Snuderl, M; Song, Y; Tannous, BA; Yamashita, H	1
Anand-Apte, B; Blobel, CP; Chan, RV; Chiang, MF; Farage, E; Glomski, K; Hewing, NJ; Khokha, R; Swendeman, S; Vermaat, J; Weskamp, G	1
Jürgensmeier, JM; Kendrew, J; Logié, A; Odedra, R; Ogilvie, DJ; Pearsall, S; Taylor, PJ; Wedge, SR	1
Armstrong, EA; Harari, PM; Huang, SM; Li, J	1
Bigley, AL; Boffey, SJ; Chester, R; Curry, B; Curwen, JO; Dukes, M; Graham, GA; Hennequin, LF; Hughes, GD; Jackson, JA; Kendrew, J; Musgrove, HL; Ogilvie, DJ; Richmond, GH; Stokes, ES; Thomas, AP; Valentine, PJ; Wadsworth, PF; Wedge, SR	1
Bruneteau, G; Clément, O; Cuénod, CA; Frija, G; Frouin, F; Kahn, E; Pradel, C; Siauve, N	1
Feng, C; Grandis, JR; Li, M; Liu, X; Riedel, F; Ye, C; Zeng, Q	1
Rosen, LS	1
Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Tortora, G; Troiani, T; Veneziani, BM; Zangemeister-Wittke, U	1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM	1
Dafni, H; Gross, DJ; Nagler, A; Neeman, M; Pines, M; Reibstein, I; Slavin, S; Weiss, L	1
Yamada, K; Yamaguchi, S; Yamamura, T	1
Bruneteau, G; Clement, O; Cuenod, CA; de Bazelaire, C; Frija, G; Frouin, F; Pradel, C; Robert, PH; Siauve, N; Tessier, JL; Wedge, SR	1
Averbuch, SD	1
Asakuma, J; Asano, T; Hayakawa, M; Sumitomo, M	1
Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N	1
Gear, RB; Heffelfinger, SC; LaDow, K; Schneider, J; Warshawsky, D; Yan, M	1
Capriotti, T	1
Hirata, A; Izumi, K; Kuwano, M; Naito, S; Ono, M; Uehara, H	1
Brousal, J; Cuneo, K; Fu, A; Geng, L; Hallahan, DE; Hayflick, JS; Himmelfarb, E; Kesicki, EA; Niermann, K; Schueneman, A; Tan, J; Treiberg, J	1
Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G	1
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X	1
Bucana, C; Ellis, LM; Fan, F; Liu, W; Mansfield, PF; McCarty, MF; Ryan, AJ; Stoeltzing, O; Wey, J	1
de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P	1
Chambers, AF; Ellis, CG; Groom, AC; MacDonald, IC; Mackenzie, LT; Ryan, A; Varghese, HJ	1
Shi, W; Siemann, DW	1
Nakanishi, Y	1
Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T	1
Conaway, M; Gulding, K; Nicholson, B; Theodorescu, D; Wedge, SR	1
Hoang-Xuan, K; Sanson, M; Thillet, J	1
Isoe, T; Kamishohara, M; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Taguchi, E; Takahashi, K; Yamamoto, A	1
Baker, CH; Beaudry, P; Folkman, J; Force, J; Heymach, JV; Johnson, BE; Naumov, GN; Ryan, A; Soker, S; Wang, A	1
Herbst, RS; Onn, A; Sandler, A	1
Drevs, J; Esser, N; Konerding, MA; Ogilvie, DJ; Ryan, AJ; Wedge, SR; Wolloscheck, T	1
Heymach, JV	1
Ryan, AJ; Wedge, SR	1
Bianco, AR; Bianco, C; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Raben, D; Ryan, A; Tortora, G	1
Hong, SJ; Jae, YW; Kim, SI; Kwon, SM; Oh, HY	1
Fridman, E; Genina, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y	1
Matsumori, Y; Muguruma, H; Nakataki, E; Sone, S; Yano, S; Yoshizumi, M; Zheng, R	1
Soff, G; Zakarija, A	1
Chen, E; Lee, CC; Lin, LC; Lin, S; Shyu, KG; Tsai, SC; Wang, BW	1
Bigner, DD; Dimery, I; Friedman, HS; Graner, MW; Kaipainen, A; Keir, ST; Kieran, MW; Laforme, A; McLendon, RE; Rasheed, BK; Reardon, DA; Rich, JN; Ryan, AJ; Sathornsumetee, S; Wang, L; Wheeler, C	1
Agarwala, SS; Tawbi, H	1
Edakuni, N; Goto, H; Kakiuchi, S; Matsumori, Y; Muguruma, H; Nakataki, E; Ryan, A; Sone, S; Tomimoto, H; Uehara, H; Yamamoto, A; Yano, S	1
Bianco, C; Ciardiello, F; Dimery, I; Frederick, B; Gustafson, D; Raben, D	1
Fu, A; Hallahan, DE; Huamani, J; Kim, DW	1
Agarwal, B; Badve, S; Hutchins, GD; Mehrotra, S; Miller, KD; Miller, M; Mock, BH; Sledge, GW; Zheng, QH	1
Connolly, CM; Lawler, J; Pines, M; Yee, KO	1
Matsunaga, N; Nakamura, K; Taguchi, E; Takahashi, K; Tsunoda, H; Yamamoto, A	1
Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M	1
Basaki, Y; Kuwano, M; Ogawa, K; Ono, M; Sakisaka, S; Ueda, S; Yoshie, M	1
Bozec, A; Fischel, JL; Milano, G	1
Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S	1
Gasparini, G; Longo, R; Sarmiento, R	1
Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W	1
Chon, HS; Hu, W; Kavanagh, JJ	1
Balvay, D; Bessoud, B; Bois, FY; Brochot, C; Cuénod, CA; Siauve, N	1
Herbst, R; Sandler, A; Vokes, E	1
Albert, JM; Cao, C; Geng, L; Ivy, PS; Johnson, DH; Lu, B; Sandler, A	1
Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y	1
Gutin, PH; Hormigo, A; Rafii, S	1
Ancukiewicz, M; Batchelor, TT; Benner, T; Cahill, DP; Chen, PJ; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Ivy, P; Jain, RK; Kozak, KR; Loeffler, JS; Louis, DN; Mrugala, MM; Plotkin, S; Scadden, DT; Sorensen, AG; Wen, PY; Zhang, WT; Zhu, M	1
Aglietta, M; Montemurro, F; Valabrega, G	1
Collins, MH; Cripe, TP; Crombleholme, TM; Currier, MA; Hsu, YH; Mahller, YY; Mehrian-Shai, R; Miller, SJ; Ratner, N; Ripberger, MC; Vaikunth, SS	1
Herbst, RS; Heymach, JV; O'Reilly, MS; Onn, A; Ryan, AJ	1
Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Komaki, R; Langley, RR; O'Reilly, MS; Onn, A; Ryan, AJ; Shibuya, K; Shitani, T; Wu, W	1
Babur, M; Shannon, AM; Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ	1
Schneider, BP; Sledge, GW	1
Chan, A; Chen, R; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P; Wheelhouse, J; Zhang, X	1
de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P	1
Courtright, J; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Tajbakhsh, M; Wu, J	1
Cabebe, E; Wakelee, H	1
Barry, ST; Copley, C; James, NH; Jürgensmeier, JM; Kendrew, J; Oakley, I; Smith, NR; Wainwright, A; Wedge, SR; Womersley, LM	1
Armand, JP; Mir, O; Ropert, S	1
Ang, K; Herbst, RS; Itasaka, S; Jürgensmeier, JM; Komaki, R; Milas, L; O'Reilly, MS; Ryan, A; Shibuya, K; Shintani, T	1
Eniu, A	1
Aliu, S; Hann, B; Hom, YK; Hylton, NM; Li, KL; Moasser, MM; Wang, D; Wilmes, LJ; Wong, CH	1
Chen, CS; Garrison, JB; Kyprianou, N; Shaw, YJ	1
Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P	1
Doyle, DM; Miller, KD	1
Giordano, S; Petrelli, A	1
Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nakataki, E; Nishioka, Y; Ogino, H; Ryan, A; Sone, S; Yamada, T; Yano, S	1
De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J	1
Lee, CB; Socinski, MA	1
Ariel, I; de-Groot, N; Elkin, M; Hochberg, A; Miao, HQ; Nagler, A; Pines, M; Vlodavsky, I	1
Abramovitch, R; Dafni, H; Nagler, A; Neeman, M; Pines, M	1
Akaike, T; Egashira, K; Funakoshi, H; Huang, P; Kandabashi, T; Miyata, K; Okamoto, S; Shimokawa, H; Takeshita, A; Yogo, K	1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Cuccato, S; Damiano, V; De Placido, S; Fontanini, G; Tortora, G	1
Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM; Zunino, F	1
Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J	1
Harris, AL; Streeter, EH	1

Reviews

59 review(s) available for quinazolines and Angiogenesis, Pathologic

Article	Year
Angiogenesis Inhibitors in NSCLC. International journal of molecular sciences, 2017, Sep-21, Volume: 18, Issue:10 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids	2017
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in oncology, 2019, Volume: 46, Issue:2 Topics: Asbestos; Bevacizumab; Carcinogenesis; Humans; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neovascularization, Pathologic; Pleural Neoplasms; Quinazolines	2019
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer, 2013, May-15, Volume: 119, Issue:10 Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation	2013
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2013 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Clinical Trials as Topic; Disease Progression; Drug Antagonism; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Biological; Myeloid Cells; Neoplasm Proteins; Neovascularization, Pathologic; Patient Selection; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Tumor Microenvironment; Vascular Endothelial Growth Factors	2013
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:11 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab	2013
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:16 Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides	2013
Progress of molecular targeted therapies for advanced renal cell carcinoma. BioMed research international, 2013, Volume: 2013 Topics: Carcinoma, Renal Cell; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A	2013
Tumor angiogenesis and anti-angiogenic therapies. Human antibodies, 2013, Volume: 22, Issue:1-2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors	2013
Development of molecular targeted drugs for advanced thyroid cancer in Japan. Endocrine journal, 2014, Volume: 61, Issue:9 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms	2014
[New targeted therapies in breast cancer]. Gynecologie, obstetrique & fertilite, 2014, Volume: 42, Issue:11 Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab	2014
Cediranib in ovarian cancer: state of the art and future perspectives. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor	2016
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. Bulletin du cancer, 2016, Volume: 103, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2016
Antiangiogenic therapy in oncology: current status and future directions. Lancet (London, England), 2016, Jul-30, Volume: 388, Issue:10043 Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2016
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome	2008
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis]. Nederlands tijdschrift voor geneeskunde, 2008, Apr-19, Volume: 152, Issue:16 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines	2008
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:4 Topics: Brain Edema; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor A	2009
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert review of anticancer therapy, 2009, Volume: 9, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future oncology (London, England), 2009, Volume: 5, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor A	2009
Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules (Basel, Switzerland), 2009, May-18, Volume: 14, Issue:5 Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Evodia; Humans; Medicine, Chinese Traditional; Neoplasms; Neovascularization, Pathologic; Plant Extracts; Quinazolines	2009
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2009, Volume: 23, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A	2009
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Experimental biology and medicine (Maywood, N.J.), 2010, Volume: 235, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A	2010
Targeted therapy: an evolving world of lung cancer. Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic	2011
Antiangiogenic therapies for malignant pleural mesothelioma. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Humans; Mesothelioma; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pleural Effusion, Malignant; Pleural Neoplasms; Quinazolines; Quinolines; Thoracic Cavity; Vascular Endothelial Growth Factors	2011
In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment	2011
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2011
[Dose finding methods for targeted agents: new perspectives]. Bulletin du cancer, 2010, Volume: 97, Issue:12 Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic	2010
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics : a review publication of the Radiological Society of North America, Inc, 2011, Volume: 31, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines	2011
Clinical experience with antiangiogenic therapy in leukemia. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. Magyar onkologia, 2012, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib	2012
Targeted therapy in brain metastasis. Current opinion in oncology, 2012, Volume: 24, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Humans; Ipilimumab; Lapatinib; Molecular Targeted Therapy; Neovascularization, Pathologic; Quinazolines	2012
Targeted agents and systemic therapy in hepatocellular carcinoma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 190 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A	2013
Inhibitors of the vascular endothelial growth factor receptor. Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors	2002
[Angiogenesis and metastasis in colorectal cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7 Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A	2003
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer. Clinical lung cancer, 2003, Volume: 5 Suppl 1 Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Quinazolines; Signal Transduction; Tumor Cells, Cultured	2003
Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. Clinical lung cancer, 2003, Volume: 5 Suppl 1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines	2003
[Anti angiogenesis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4 Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A	2004
New oncology strategy: molecular targeting of cancer cells. Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 2004, Volume: 13, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A	2004
[Does molecular targeted therapy change the treatment for lung cancer?]. Fukuoka igaku zasshi = Hukuoka acta medica, 2004, Volume: 95, Issue:9 Topics: Antineoplastic Agents; Cell Cycle; Gefitinib; Genes, erbB-1; Genetic Therapy; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Suppressor Protein p53; Vaccines, Synthetic	2004
Molecular changes in gliomas. Current opinion in oncology, 2004, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Epidermal Growth Factor; Gefitinib; Glioma; Humans; Neovascularization, Pathologic; Quinazolines	2004
Angiogenesis and lung cancer: prognostic and therapeutic implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-10, Volume: 23, Issue:14 Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib	2005
ZD6474--clinical experience to date. British journal of cancer, 2005, Volume: 92 Suppl 1 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A	2005
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. British journal of cancer, 2005, Volume: 92 Suppl 1 Topics: Administration, Oral; Biological Availability; Cell Survival; Drug Administration Schedule; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction	2005
Update on angiogenesis inhibitors. Current opinion in oncology, 2005, Volume: 17, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2005
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Current opinion in oncology, 2006, Volume: 18, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neovascularization, Pathologic; Piperidines; Protein-Tyrosine Kinases; Quinazolines	2006
Anti-angiogenic and anti-HER therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2006, Volume: 60, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor	2006
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Current cancer drug targets, 2006, Volume: 6, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A	2006
Targeted therapies in gynecologic cancers. Current cancer drug targets, 2006, Volume: 6, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Transfer Techniques; Genital Neoplasms, Female; Humans; Neovascularization, Pathologic; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thalidomide; Thionucleotides; Trastuzumab	2006
Angiogenesis inhibition in the treatment of lung cancer. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:11 Suppl 2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A	2006
Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer cell, 2007, Volume: 11, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Quinazolines	2007
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2007
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:2 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction	2007
Drug insight: VEGF as a therapeutic target for breast cancer. Nature clinical practice. Oncology, 2007, Volume: 4, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Humans; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A	2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Current treatment options in oncology, 2007, Volume: 8, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1	2007
[Oral drugs inhibiting the VEGF pathway]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2007
Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2007, Volume: 12 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Heart Diseases; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A	2007
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Current medicinal chemistry, 2008, Volume: 15, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab	2008
[Targeted therapies in the treatment of non-small cell lung cancer]. Bulletin du cancer, 2008, Volume: 95, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1	2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Reviews on recent clinical trials, 2007, Volume: 2, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome	2007
Angiogenesis in bladder cancer--prognostic marker and target for future therapy. Surgical oncology, 2002, Volume: 11, Issue:1-2 Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Cyclohexanes; DNA-Binding Proteins; Drug Combinations; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Nuclear Proteins; O-(Chloroacetylcarbamoyl)fumagillol; Piperidines; Quinazolines; Quinazolinones; Sesquiterpenes; Thymidine Phosphorylase; Transcription Factors; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002

Trials

5 trial(s) available for quinazolines and Angiogenesis, Pathologic

Article	Year
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension (Dallas, Tex. : 1979), 2011, Volume: 58, Issue:1 Topics: Administration, Oral; Adult; Aged; Blood Pressure; Breast Neoplasms; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Middle Aged; Neovascularization, Pathologic; Nitric Oxide; Piperidines; Prospective Studies; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Cells, Cultured; Vasodilation	2011
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. Radiology, 2012, Volume: 265, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium DTPA; Humans; Iohexol; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome	2012
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast cancer research and treatment, 2012, Volume: 136, Issue:1 Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Blood Platelets; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Platelet Factor 4; Proteomics; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1	2012
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer cell, 2007, Volume: 11, Issue:1 Topics: Brain Edema; Brain Neoplasms; Chemokine CXCL12; Chemokines, CXC; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Flow Cytometry; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis	2007

Other Studies

156 other study(ies) available for quinazolines and Angiogenesis, Pathologic

Article	Year
Fruquintinib and its use in the treatment of metastatic colorectal cancer. Future oncology (London, England), 2019, Volume: 15, Issue:22 Topics: Angiogenesis Inhibitors; Benzofurans; Cell Proliferation; China; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2019
The Noonan Syndrome Gene Circulation research, 2020, 05-08, Volume: 126, Issue:10 Topics: Animals; Blood Vessels; Carcinoma, Lewis Lung; Disease Models, Animal; Endosomal Sorting Complexes Required for Transport; Endosomes; Endothelial Cells; Haploinsufficiency; HeLa Cells; Hemorrhage; Humans; Lymphokines; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Noonan Syndrome; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Signal Transduction; Transcription Factors; Ubiquitination; Vascular Endothelial Growth Factor Receptor-2; Vascular Malformations	2020
Evodiamine inhibits vasculogenic mimicry in HCT116 cells by suppressing hypoxia-inducible factor 1-alpha-mediated angiogenesis. Anti-cancer drugs, 2021, 03-01, Volume: 32, Issue:3 Topics: Animals; Antigens, CD; Cadherins; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Female; HCT116 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor A; Wound Healing	2021
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. International journal of molecular sciences, 2021, Mar-16, Volume: 22, Issue:6 Topics: Angiogenesis Inhibitors; Anilides; Animals; Apoptosis; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Embryo, Nonmammalian; Humans; Neovascularization, Pathologic; Neovascularization, Physiologic; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms; Zebrafish	2021
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. Anti-cancer drugs, 2021, 10-01, Volume: 32, Issue:9 Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chemoembolization, Therapeutic; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia; Liver Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factors	2021
Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 98 Topics: Animals; Cell Line, Tumor; Crown Ethers; Epithelial Cells; ErbB Receptors; Female; Guinea Pigs; Humans; Mice; Mice, Inbred ICR; Mitosis; Models, Animal; Neovascularization, Pathologic; Psoriasis; Quinazolines; Signal Transduction	2018
Gefitinib inhibits retina angiogenesis by affecting VEGF signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 102 Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Cyclin E; Cyclin-Dependent Kinase 2; Disease Models, Animal; Gefitinib; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxygen; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Retinal Diseases; Retinal Vessels; Vascular Endothelial Growth Factor A	2018
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma. Cancer biomarkers : section A of Disease markers, 2018, Volume: 22, Issue:4 Topics: Adult; Aged; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Stomach Neoplasms; Vascular Endothelial Growth Factor A	2018
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene, 2018, Volume: 37, Issue:42 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, Inbred NOD; Naphthalenes; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pyrimidines; Quinazolines; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Vascular Endothelial Growth Factor Receptor-1	2018
EGFR inhibitor, AG1478, inhibits inflammatory infiltration and angiogenesis in mice with diabetic retinopathy. Clinical and experimental pharmacology & physiology, 2019, Volume: 46, Issue:1 Topics: Animals; Diabetic Retinopathy; Disease Progression; ErbB Receptors; Female; Inflammation; Macrophages; Male; Mice; Mitochondria; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Retinal Vessels; Tyrphostins	2019
Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth. Molecular cancer therapeutics, 2013, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays	2013
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. The Journal of clinical investigation, 2013, Volume: 123, Issue:4 Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Diphenylamine; Feedback, Physiological; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2013
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway. International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment	2013
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Dacarbazine; Drug Synergism; Extracellular Fluid; Glioma; Humans; Male; Microdialysis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays	2013
A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis. Molecular medicine reports, 2013, Volume: 8, Issue:2 Topics: Animals; Capillary Permeability; Disease Models, Animal; Inflammation; Mice; Mice, Transgenic; Neovascularization, Pathologic; Psoriasis; Quinazolines; Skin; T-Lymphocytes; Thiadiazoles; Vascular Endothelial Growth Factor Receptor-2	2013
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer. The Journal of surgical research, 2013, Volume: 185, Issue:2 Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays	2013
Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties. European journal of medicinal chemistry, 2013, Volume: 67 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; HT29 Cells; Humans; MCF-7 Cells; Mice; Models, Molecular; Molecular Structure; Neovascularization, Pathologic; NIH 3T3 Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Structure-Activity Relationship	2013
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib	2013
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Scientific reports, 2013, Oct-04, Volume: 3 Topics: Animals; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; Erlotinib Hydrochloride; Glioma; Heme; Heterografts; Humans; Mice; Molecular Imaging; Neovascularization, Pathologic; Optical Imaging; Permeability; Pharmaceutical Preparations; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2013
Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma. Neuro-oncology, 2013, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Capillary Permeability; Drug Synergism; Female; Glioma; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Quinacrine; Quinazolines; Tumor Burden; Tumor Cells, Cultured	2013
Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Annals of surgical oncology, 2014, Volume: 21, Issue:2 Topics: Animals; Apoptosis; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oncolytic Virotherapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Simplexvirus; Survival Rate; Tumor Cells, Cultured; Virus Internalization; Virus Replication; Xenograft Model Antitumor Assays	2014
Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5. Oncotarget, 2013, Volume: 4, Issue:12 Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Gene Expression; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Kinesins; Mice; Mitosis; Neovascularization, Pathologic; Quinazolines; Recombinant Proteins; Thiones; Vascular Endothelial Growth Factor A; Zebrafish	2013
[Investigation of the venodilatory effect of vascular endothelial growth factor (VEGF) in rat gingiva]. Fogorvosi szemle, 2013, Volume: 106, Issue:2 Topics: Animals; Capillary Permeability; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gingiva; Immunohistochemistry; Male; Neovascularization, Pathologic; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Quinazolines; Rats; Rats, Wistar; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vasodilation; Venules	2013
Tryptanthrin inhibits angiogenesis by targeting the VEGFR2-mediated ERK1/2 signalling pathway. PloS one, 2013, Volume: 8, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Cell Line; Cell Proliferation; Drugs, Chinese Herbal; Endothelial Cells; Humans; MAP Kinase Signaling System; Mice; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Wound Healing	2013
Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. ChemMedChem, 2014, Volume: 9, Issue:4 Topics: Animals; Antineoplastic Agents; Blood Vessels; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endothelial Cells; HCT116 Cells; HT29 Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Structure-Activity Relationship	2014
Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors. European journal of medicinal chemistry, 2014, May-22, Volume: 79 Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured; Urea; Vascular Endothelial Growth Factor Receptor-2	2014
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. Experimental cell research, 2014, Aug-15, Volume: 326, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Mutation; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases	2014
Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Calcium-Binding Proteins; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Female; Focal Adhesion Protein-Tyrosine Kinases; Gefitinib; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays	2014
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:6 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A	2014
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA‑1 cells. Molecular medicine reports, 2014, Volume: 10, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Crotoxin; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines	2014
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis. PloS one, 2014, Volume: 9, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Discovery; Enzyme Activation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Quinazolines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2014
Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels. Annals of biomedical engineering, 2015, Volume: 43, Issue:9 Topics: Cell Line, Tumor; Coculture Techniques; Human Umbilical Vein Endothelial Cells; Humans; Hydrogels; Intercellular Signaling Peptides and Proteins; Mechanotransduction, Cellular; Neoplasms; Neovascularization, Pathologic; Piperidines; Polyethylene Glycols; Quinazolines	2015
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique, Indirect; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Quinazolines	2015
Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat model. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:2 Topics: Animals; Cell Proliferation; Disease Models, Animal; Endometriosis; Female; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor Receptor-2	2015
The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis. Molecules and cells, 2015, Volume: 38, Issue:6 Topics: Animals; Azepines; Carcinoma, Hepatocellular; Chick Embryo; Enzyme Inhibitors; Hep G2 Cells; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Quinazolines; Signal Transduction	2015
DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria. Scientific reports, 2015, Jun-10, Volume: 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Apocynaceae; Apoptosis; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Humans; Melanoma; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Plant Extracts; Plant Leaves; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2015
Can the Lung Cancer Pie Be Divided into Angiogenic Slices? Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Dec-01, Volume: 21, Issue:23 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines	2015
Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 90, Issue:2 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2015
Novel Etoposide Analogue Modulates Expression of Angiogenesis Associated microRNAs and Regulates Cell Proliferation by Targeting STAT3 in Breast Cancer. PloS one, 2015, Volume: 10, Issue:11 Topics: Apoptosis; Breast Neoplasms; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Enzyme Activation; Etoposide; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; MicroRNAs; Models, Molecular; Molecular Docking Simulation; Neovascularization, Pathologic; Podophyllotoxin; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A	2015
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. International journal of cancer, 2016, May-15, Volume: 138, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Models, Animal; Female; Gene Expression; Humans; MAP Kinase Signaling System; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Tumor Burden; Xenograft Model Antitumor Assays	2016
miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2. Oncotarget, 2016, Mar-01, Volume: 7, Issue:9 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Paclitaxel; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2016, Apr-19, Volume: 113, Issue:16 Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Drug Screening Assays, Antitumor; Glioblastoma; Macrophages; Mice; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic	2016
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Cancer letters, 2016, 08-28, Volume: 379, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta	2016
Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Evodia; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phytotherapy; Plant Extracts; Quinazolines; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2016
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways. Scientific reports, 2016, 09-16, Volume: 6 Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Colony-Forming Units Assay; Drug Design; Drug Discovery; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Rats, Sprague-Dawley; Signal Transduction; Stress Fibers; Thiazoles; Wound Healing	2016
Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Oncotarget, 2017, Feb-07, Volume: 8, Issue:6 Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays	2017
Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. Cancer letters, 2017, 02-01, Volume: 386 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays	2017
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Scientific reports, 2017, 03-13, Volume: 7 Topics: Anoikis; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Gefitinib; Glioblastoma; Humans; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor	2017
The Different Effects of VEGFA121 and VEGFA165 on Regulating Angiogenesis Depend on Phosphorylation Sites of VEGFR2. Inflammatory bowel diseases, 2017, Volume: 23, Issue:4 Topics: Anilides; Animals; Colitis, Ulcerative; Colon; Intestinal Mucosa; Neovascularization, Pathologic; Phosphorylation; Protein Isoforms; Pyridines; Quinazolines; Rats; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2017
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer research, 2008, Jun-15, Volume: 68, Issue:12 Topics: Adenoviridae; Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Membrane Permeability; Cell Movement; Cell Proliferation; Cell Survival; Endothelium, Vascular; Humans; Immunoprecipitation; Lymphangiogenesis; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Signal Transduction; Skin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2008
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Analysis of Variance; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A	2008
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:13 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Tongue Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2008
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. International journal of oncology, 2008, Volume: 33, Issue:3 Topics: Animals; Apoptosis; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Necrosis; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2008
Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World journal of gastroenterology, 2008, Sep-21, Volume: 14, Issue:35 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2008
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. Neoplasia (New York, N.Y.), 2009, Volume: 11, Issue:1 Topics: Adenocarcinoma; Adenoviridae; Animals; Antineoplastic Agents; Cell Proliferation; Cone-Beam Computed Tomography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, p53; Genes, ras; Lung Neoplasms; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; Quinazolines; Tumor Burden	2009
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Mar-01, Volume: 15, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured	2009
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11 Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Organ Culture Techniques; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; RNA Interference; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2009
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer research, 2009, Volume: 29, Issue:6 Topics: Animals; Carcinoma, Squamous Cell; Cell Movement; Colonic Neoplasms; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2009
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvascular research, 2009, Volume: 78, Issue:3 Topics: Animals; Antigens; Antineoplastic Agents; Blood Vessels; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; ErbB Receptors; Gefitinib; Humans; Image Processing, Computer-Assisted; Melanoma; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Skin Neoplasms	2009
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia (New York, N.Y.), 2009, Volume: 11, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Piperidines; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays	2009
Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity. International journal of oncology, 2009, Volume: 35, Issue:6 Topics: Antineoplastic Agents; Blotting, Western; Chemotaxis; Down-Regulation; Endothelial Cells; Fibroblast Growth Factor 2; Gefitinib; Humans; Neovascularization, Pathologic; Protein Structure, Tertiary; Proto-Oncogene Proteins c-fes; Quinazolines; Vascular Endothelial Growth Factor A	2009
Acoustic radiation force and optical spectroscopy for assessing tumor vessel normalization during anti-angiogenic therapy. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2009, Volume: 2009 Topics: Acoustics; Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Cell Line, Tumor; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrum Analysis; Treatment Outcome	2009
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. Anticancer research, 2009, Volume: 29, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Disease Models, Animal; Female; Immunoenzyme Techniques; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A	2009
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer, 2010, May-15, Volume: 116, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Humans; Isotretinoin; Mice; Neovascularization, Pathologic; Neuroblastoma; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2010
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Molecular cancer therapeutics, 2010, Volume: 9, Issue:4 Topics: Animals; bcl-X Protein; Brain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Glioma; Humans; Magnetic Resonance Imaging; Mice; Mutant Proteins; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays	2010
Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Molecular imaging and biology, 2010, Volume: 12, Issue:6 Topics: Animals; Cell Line, Tumor; Contrast Media; ErbB Receptors; Humans; Mice; Mice, Nude; Mice, Transgenic; Models, Biological; Molecular Imaging; Neoplasms; Neovascularization, Pathologic; Polyethylene Glycols; Positron-Emission Tomography; Quinazolines; Xenograft Model Antitumor Assays	2010
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer research, 2010, May-01, Volume: 70, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neurilemmoma; Neurofibromatosis 2; Neurofibromin 2; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A	2010
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC cancer, 2010, May-11, Volume: 10 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Endothelial Cells; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stem Cells; Time Factors; Xenograft Model Antitumor Assays	2010
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer research, 2010, Jun-01, Volume: 70, Issue:11 Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays	2010
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinogens; Chemoprevention; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Urethane; Vascular Endothelial Growth Factor Receptor-2	2010
Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Clinical breast cancer, 2010, Volume: 10 Suppl 2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2010
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:9 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Contrast Media; Humans; Image Enhancement; Kinetics; Male; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Nude; Time Factors; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays	2010
Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer research, 2010, Nov-01, Volume: 70, Issue:21 Topics: Animals; Blotting, Western; Bone Neoplasms; Brain Neoplasms; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Quinazolines; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2010
Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:11 Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Immunohistochemistry; Mice; Mice, Inbred CBA; Mouth Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor	2010
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Immunoblotting; In Situ Nick-End Labeling; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2011
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. The Journal of pathology, 2011, Volume: 223, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2011
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Burden; Xenograft Model Antitumor Assays	2011
SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endothelial Cells; Female; Hep G2 Cells; Humans; Melanoma, Experimental; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Quinazolines; Signal Transduction; Thiadiazoles; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Zebrafish	2011
EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model. The Journal of surgical research, 2012, Volume: 173, Issue:1 Topics: Angiography; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; In Vitro Techniques; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Sarcoma, Ewing; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2012
Cardiovascular toxicity profiles of vascular-disrupting agents. The oncologist, 2011, Volume: 16, Issue:8 Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones	2011
Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. Anti-cancer drugs, 2012, Volume: 23, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Injections, Intraperitoneal; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2012
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clinical & experimental metastasis, 2012, Volume: 29, Issue:3 Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand	2012
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays	2012
A case of choroidal metastasis of lung cancer successfully treated with erlotinib. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines	2012
Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis. Journal of immunology (Baltimore, Md. : 1950), 2012, Apr-01, Volume: 188, Issue:7 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Becaplermin; Cell Division; Cyclooxygenase 2; Cytokines; Drug Evaluation, Preclinical; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred DBA; Neovascularization, Pathologic; Osteoclasts; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Quinazolines; Synovial Membrane	2012
Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Molecular cancer therapeutics, 2012, Volume: 11, Issue:7 Topics: Aged; Animals; Antineoplastic Agents; Benzodioxoles; Biliary Tract Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phosphorylation; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays	2012
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. Journal of hepatology, 2012, Volume: 57, Issue:3 Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A	2012
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism. Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:8 Topics: Animals; Antioxidants; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Blotting, Western; Butylated Hydroxytoluene; Carcinogens; Cell Proliferation; Cytokines; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Hypoxia; Immunoenzyme Techniques; Lung Neoplasms; Methylcholanthrene; Mice; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-myc; Pulmonary Alveoli; Quinazolines; Sleep Apnea Syndromes; Urethane; Vascular Endothelial Growth Factor Receptor-2	2012
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. The American journal of pathology, 2012, Volume: 181, Issue:3 Topics: Aminopyridines; Animals; Antibodies; Antibody Specificity; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Models, Biological; Mutation; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2012
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides	2012
Microvascular regulatory role and increased expression of vascular endothelial growth factor receptor type 2 in experimental gingivitis. Journal of periodontal research, 2013, Volume: 48, Issue:2 Topics: Animals; Capillary Permeability; Endothelium, Vascular; Gingiva; Gingivitis; Male; Muscle, Smooth, Vascular; Neovascularization, Pathologic; Pericytes; Quinazolines; Random Allocation; Rats; Rats, Wistar; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vasoconstrictor Agents; Vasodilator Agents; Venules	2013
Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro. British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10 Topics: Angiogenic Proteins; Cell Proliferation; Humans; Indoles; Meningeal Neoplasms; Meningioma; Neovascularization, Pathologic; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-sis; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor A; Xanthones	2012
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America, 2012, Nov-06, Volume: 109, Issue:45 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Death; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Female; Gene Amplification; Humans; Killer Cells, Natural; Lapatinib; Mice; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays	2012
Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice. Investigative ophthalmology & visual science, 2013, Jan-30, Volume: 54, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Intravitreal Injections; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Oxygen; Protein Kinase Inhibitors; Quinazolines; Retinal Diseases; Signal Transduction; Tissue Inhibitor of Metalloproteinase-3	2013
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Mice; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Burden; Xenograft Model Antitumor Assays	2013
Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer research, 2002, Aug-01, Volume: 62, Issue:15 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Endothelium, Vascular; ErbB Receptors; Female; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2002
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer research, 2002, Aug-15, Volume: 62, Issue:16 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Endothelial Growth Factors; Enzyme Inhibitors; Female; Humans; Lymphokines; Male; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays	2002
Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. Academic radiology, 2002, Volume: 9 Suppl 2 Topics: Animals; Capillary Permeability; Contrast Media; Endothelial Growth Factors; Gadolinium; Heterocyclic Compounds; Intercellular Signaling Peptides and Proteins; Lymphokines; Macromolecular Substances; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Organometallic Compounds; Perfusion; Prostatic Neoplasms; Quinazolines; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:11 Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Cells, Cultured; Collagen; Down-Regulation; Endostatins; Endothelium, Vascular; ErbB Receptors; Humans; Immunohistochemistry; Liposomes; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Peptide Fragments; Plasmids; Quinazolines; Recombinant Proteins; Time Factors; Transfection; Tumor Cells, Cultured; Umbilical Veins	2002
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Death; Cell Division; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotides; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4 Topics: Agar; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Isoenzymes; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Prostaglandin-Endoperoxide Synthases; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Sulfonamides	2003
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-01, Volume: 9, Issue:10 Pt 1 Topics: Animals; Antineoplastic Agents; Cell Division; Collagen; Collagen Type I; Disease Progression; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pheochromocytoma; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Temperature; Time Factors; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein	2003
Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magnetic resonance imaging, 2003, Volume: 21, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Contrast Media; Magnetic Resonance Angiography; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Triazoles; Vascular Endothelial Growth Factor A	2003
Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. The Journal of urology, 2004, Volume: 171, Issue:2 Pt 1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Division; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Quinazolines	2004
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation. Laboratory investigation; a journal of technical methods and pathology, 2004, Volume: 84, Issue:8 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Base Sequence; Carcinoma in Situ; DNA Primers; Female; Humans; Hyperplasia; Mammary Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor Receptor-2	2004
Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer science, 2004, Volume: 95, Issue:7 Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Endothelial Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines	2004
A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer research, 2004, Jul-15, Volume: 64, Issue:14 Topics: Animals; Catalytic Domain; Cell Movement; Cell Survival; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Humans; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents	2004
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft Molecular cancer therapeutics, 2004, Volume: 3, Issue:8 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors	2004
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17 Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins	2004
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Molecular cancer therapeutics, 2004, Volume: 3, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Capillaries; Cell Proliferation; Endothelial Cells; ErbB Receptors; Humans; Mice; Neovascularization, Pathologic; Pericytes; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Stomach Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2	2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1 Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Melanoma; Mice; Mice, Inbred BALB C; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotides, Antisense; Phenotype; Piperidines; Placebos; Quinazolines; RNA; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor A	2004
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis, 2004, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Cell Line, Transformed; Disease Models, Animal; Female; Liver Neoplasms; Mice; Mice, SCID; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines	2004
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. International journal of radiation oncology, biology, physics, 2004, Nov-15, Volume: 60, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines; Sarcoma, Kaposi	2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer science, 2004, Volume: 95, Issue:12 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays	2004
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Androgens; Angiogenesis Inhibitors; Animals; Castration; Cell Division; Combined Modality Therapy; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Orchiectomy; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2004
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Molecular cancer therapeutics, 2004, Volume: 3, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Colonic Neoplasms; Endothelial Cells; Enzyme Activation; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Prostatic Neoplasms; Quinazolines; Rats; Rats, Nude; Transplantation, Heterologous; Tyrosine; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2	2004
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9 Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelial Cells; Flow Cytometry; Immunohistochemistry; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neovascularization, Pathologic; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-kit; Quinazolines; Stem Cells; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2005
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis, 2004, Volume: 7, Issue:4 Topics: Animals; Blood Vessels; Carcinoma, Renal Cell; Cell Division; Enzyme Inhibitors; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines	2004
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15 Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Collagen; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Glioblastoma; Humans; Immunohistochemistry; In Vitro Techniques; Laminin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Proteoglycans; Quinazolines; Radiation, Ionizing; Time Factors; Vascular Endothelial Growth Factor A	2005
Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model. Urologia internationalis, 2005, Volume: 75, Issue:2 Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Renal Cell; Cell Proliferation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Quinazolines; Sensitivity and Specificity; Transplantation, Heterologous; Tumor Cells, Cultured	2005
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. The Journal of urology, 2005, Volume: 174, Issue:4 Pt 2 Topics: Angiogenesis Inhibitors; Animals; Cell Line; Child, Preschool; Collagen; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Injections, Intraperitoneal; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones; Receptor, ErbB-2; Transplantation, Heterologous; Wilms Tumor; WT1 Proteins	2005
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clinical & experimental metastasis, 2005, Volume: 22, Issue:3 Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; In Vitro Techniques; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Mas; Quinazolines; src-Family Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2005
Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life sciences, 2006, Apr-04, Volume: 78, Issue:19 Topics: Angiogenesis Inhibitors; Capillaries; Cell Differentiation; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Endothelial Cells; Endothelium, Vascular; Humans; Neovascularization, Pathologic; Plant Extracts; Quinazolines	2006
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-15, Volume: 11, Issue:22 Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Ependymoma; ErbB Receptors; Glioma; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays	2005
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Quinazolines; Vascular Endothelial Growth Factor A	2005
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Humans; Killer Cells, Natural; Lung Neoplasms; Lymphocyte Depletion; Mice; Mice, SCID; Neovascularization, Pathologic; Piperidines; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays	2005
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. International journal of radiation oncology, biology, physics, 2006, Jan-01, Volume: 64, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2	2006
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. International journal of radiation oncology, biology, physics, 2006, Jan-01, Volume: 64, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A	2006
A physiologic imaging pilot study of breast cancer treated with AZD2171. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Mice; Neovascularization, Pathologic; Pilot Projects; Positron-Emission Tomography; Quinazolines; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2006
Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer biology & therapy, 2006, Volume: 5, Issue:2 Topics: Animals; Antigens, Viral, Tumor; Antineoplastic Agents; Breast Neoplasms; Collagen Type I; Mice; Mice, Transgenic; Neovascularization, Pathologic; Piperidines; Polyomavirus; Quinazolines; Quinazolinones; Smad2 Protein; Smad3 Protein; Thrombospondin 1; Transforming Growth Factor beta; Tumor Burden	2006
Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. Molecular cancer therapeutics, 2006, Volume: 5, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood Vessels; Body Weight; Crystallization; Drug Compounding; Drug Stability; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Rats; Rats, Sprague-Dawley; Solubility; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2006
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2006
PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer research, 2006, May-15, Volume: 66, Issue:10 Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Chemokine CXCL1; Chemokines, CXC; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Dosage; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A	2006
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncology research, 2006, Volume: 16, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2	2006
Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging. Magnetic resonance imaging, 2006, Volume: 24, Issue:8 Topics: Animals; Bayes Theorem; Contrast Media; Heterocyclic Compounds; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Quinazolines; Triazoles; Xenograft Model Antitumor Assays	2006
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer research, 2006, Dec-01, Volume: 66, Issue:23 Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Radiation; Endothelial Cells; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2006
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncology reports, 2007, Volume: 17, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines	2007
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Molecular therapy : the journal of the American Society of Gene Therapy, 2007, Volume: 15, Issue:2 Topics: Animals; Cell Line; Cell Line, Tumor; Cells, Cultured; Chlorocebus aethiops; ErbB Receptors; Erlotinib Hydrochloride; Genetic Therapy; Humans; Immunoblotting; In Situ Hybridization; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Nerve Sheath Neoplasms; Oligonucleotide Array Sequence Analysis; Oncolytic Virotherapy; Protein Kinase Inhibitors; Quinazolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Simplexvirus; Vero Cells; Xenograft Model Antitumor Assays	2007
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Molecular cancer therapeutics, 2007, Volume: 6, Issue:2 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; ErbB Receptors; Flow Cytometry; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2007
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Molecular cancer therapeutics, 2007, Volume: 6, Issue:2 Topics: Animals; Cell Hypoxia; Cell Proliferation; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred CBA; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Survival Rate; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2007
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. British journal of cancer, 2007, Mar-26, Volume: 96, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Growth Inhibitors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2007
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene, 2007, Aug-23, Volume: 26, Issue:39 Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatric blood & cancer, 2008, Volume: 50, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays	2008
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Molecular cancer therapeutics, 2007, Volume: 6, Issue:8 Topics: Animals; Antibodies, Neoplasm; Antibodies, Phospho-Specific; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Phosphotyrosine; Quinazolines; Reproducibility of Results; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2007
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pleural Effusion; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2007
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of magnetic resonance imaging : JMRI, 2007, Volume: 26, Issue:6 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capillary Permeability; Contrast Media; Gadolinium DTPA; Gefitinib; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor	2007
Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer research, 2007, Dec-01, Volume: 67, Issue:23 Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Chickens; Chorioallantoic Membrane; Doxazosin; Endothelium, Vascular; Humans; Integrin beta1; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Quinazolines; Umbilical Veins	2007
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Molecular cancer therapeutics, 2008, Volume: 7, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Humans; Mice; Neovascularization, Pathologic; Piperidines; Quinazolines; Temozolomide; Xenograft Model Antitumor Assays	2008
Development of new targeted therapies for breast cancer. Breast cancer (Tokyo, Japan), 2008, Volume: 15, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Female; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Trastuzumab	2008
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer letters, 2008, Jun-28, Volume: 265, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Rearrangement; Humans; Male; Mesothelioma; Mice; Mice, SCID; Molecular Sequence Data; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Pleural Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2008
Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer research, 1999, Aug-15, Volume: 59, Issue:16 Topics: Animals; Antineoplastic Agents; Cell Division; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Stromal Cells; Tumor Cells, Cultured; Urinary Bladder Neoplasms	1999
Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia (New York, N.Y.), 1999, Volume: 1, Issue:4 Topics: Animals; Antineoplastic Agents; Collagen; Dose-Response Relationship, Drug; In Situ Hybridization; Kinetics; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Time Factors; Tumor Cells, Cultured; Wound Healing	1999
Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arteriosclerosis, thrombosis, and vascular biology, 2000, Volume: 20, Issue:11 Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Aspirin; Carotid Arteries; Female; Fibrinolytic Agents; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Quinazolines; Tunica Intima	2000
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Synergism; Endothelial Growth Factors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Growth Substances; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays	2001
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligodeoxyribonucleotides, Antisense; Ovarian Neoplasms; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001
Growth inhibition of prostate cancer xenografts by halofuginone. The Prostate, 2002, May-01, Volume: 51, Issue:2 Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones	2002